AbbVie Inc. · NYSE:ABBV

AbbVie — Merger or Acquisition (June 2019)

28 slides from AbbVie's merger presentation, Jun 25, 2019

  1. Slide 1: Creating a New Diversified Biopharmaceutical Company

    Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019

  2. Slide 2: No Offer or Solicitation

    NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the

  3. Slide 3: Statement Required by the Irish Takeover Rules

    STATEMENT REQUIRED BY THE IRISH TAKEOVER RULES The directors of AbbVie accept responsibility for the information contained in this presentation. To the best of the knowledge and belief of the directors of AbbVie (who have taken all reasonable care to ensure that such is the case), the information co

  4. Slide 4: Creates a New Diversified Biopharmaceutical Company, Well-Positioned for Sustainable Growth

    Creates a New Diversified Biopharmaceutical Company, Well-Positioned for Sustainable Growth 1 Unique opportunity to acquire attractive and durable growth assets at a highly compelling value • Leverage AbbVie commercial strength and international infrastructure across Allergan’s therapeutic segments

  5. Slide 5: Financially Compelling Transaction

    Financially Compelling Transaction • Each Allergan share will be exchanged for $120.30 in cash and 0.8660 share of combined company (fixed exchange ratio). AbbVie shareholders to own 83% of AbbVie (on a fully diluted basis) and Allergan shareholders to own 17% • Total consideration of $188.24 per Al

  6. Slide 6: Allergan Business is a Collection of Highly Attractive, Durable Growth Assets

    Allergan Business is a Collection of Highly Attractive, Durable Growth Assets $15.7BN • Opportunity for significant market expansion; very durable cash pay business MEDICAL $4.3BN • Botox is leading cosmetic neurotoxin; Allergan has unrivaled product bundle AESTHETICS • Positioned to deliver strong,

  7. Slide 7: Combined Company Comprised of Diverse Portfolio with Leadership Positions

    Combined Company Comprised of Diverse Portfolio with Leadership Positions in Attractive, High-Growth Markets Immunology Hematologic Medical Neuroscience Other Oncology Aesthetics Franchises • Established leadership • Established leadership • Global leadership position • Multiple growth • Women’s Hea

  8. Slide 8: Combination Creates an Attractive Growth Platform that is Immediately at Scale with Peers

    Combination Creates an Attractive Growth Platform that is Immediately at Scale with Peers 2018 Revenue ($BN) 2018 Operating Cash Flow ($BN) $90 $25 82 22 $80 20 $70 $20 19 58 $60 16 54 $15 14 49 13 $50 45 42 42 41 11 11 11 38 10 $40 33 32 $10 29 8 $30 25 24 23 7 22 22 6 6 6 6 5 $20 16 15 $5 3 $10 $0

  9. Slide 9: AbbVie Comprised of Two High Value Components

    AbbVie Comprised of Two High Value Components Provides immediate scale and profitability to AbbVie’s Growth Platform AbbVie Today New AbbVie Growth Humira Humira Growth Platform $19BN $19BN Platform $14BN >$29BN  Humira supports  Approximately 60% of  Less than 40% of total  Standalone scale in

  10. Slide 10: New AbbVie Growth Platform Provides Top-Tier Revenue Growth

    New AbbVie Growth Platform Provides Top-Tier Revenue Growth 2018 – 2023 Revenue CAGR Expect High-Single Digit Growth 10% 9% 9.2% 8% 7% 6% 5% 4% 4.4% 4.4% 4.2% Peer Average 3.1% 3% 3.4% 3.2% 3.1% 2.9% 2% 1.9% 1% 1.0% 0% 0.0% -0.1% -1% New AZN GSK BMY MRK ROG JNJ SAN PFE LLY GILD NVS AMGN AbbVie Growt

  11. Slide 11: Potential for Substantial Value Creation

    Potential for Substantial Value Creation  The transaction offers significant and immediate accretion* and an attractive ROIC • Expect 10% accretion over the first year of combination, with peak accretion of greater than 20% • Expect >$2BN in annual pre-tax synergies and cost savings** in year 3 whi

  12. Slide 12: Commercial Presence

    (e\e)@)v/(— Commercial Presence

  13. Slide 13: Market Leadership in Attractive, Growth Markets

    Market Leadership in Attractive, Growth Markets #1 #2 #1 Position in Position in Position in Immunology Hematologic Medical Oncology Aesthetics Leadership #1 Leadership Position in Position in Position in Women’s Health Global HCV Eye Care 13

  14. Slide 14: Immunology

    Immunology Developing Industry-Leading Portfolio of Transformational Therapies to Address Large and Growing $65BN* Market Current–2020 2021–2023 2023+ LAUNCH PIPELINE AND INDICATION DELIVER THE NEXT ADVANCE THE NEXT MAXIMIZE HUMIRA EXPANSION TRANSFORMATIVE GENERATION THERAPY OF INNOVATION  Achieve

  15. Slide 15: Hematologic Oncology

    Hematologic Oncology Established Market Leadership Position in $40BN* Hematologic Malignancies Market Develop Imbruvica and Venclexta as Launched: 2016 1 essential treatments in optimizing patient outcomes across multiple hematologic malignancies  First-in-class BTK inhibitor  4 FDA Breakthrough T

  16. Slide 16: Medical Aesthetics

    Medical Aesthetics Leadership in an Attractive and Growing $12BN* Market New product introduction and global expansion will drive significant growth for Medical Aesthetics business Aesthetics Market Launch 1-2 New Products Per Year Growth Catalysts Over Next Several Years  Increasing interest and a

  17. Slide 17: Neuroscience

    Neuroscience Allergan Product Portfolio Provides Immediate Scale to AbbVie Allergan AbbVie  Duopa has established AbbVie presence in  Vraylar continues to be the fastest growing the advanced Parkinson’s disease market branded antipsychotic • Recently approved for bipolar depression • ABBV-951 in P

  18. Slide 18: Other Key Franchises

    Other Key Franchises Market Leadership Positions in HCV, Women’s Health and Eye Care HCV Women’s Health  HCV represents large global market, sustainable  Elagolix represents significant advance for into the mid-2020s women suffering from endometriosis and uterine fibroids  Mavyret holds leadershi

  19. Slide 19: AbbVie Commercial Excellence

    AbbVie Commercial Excellence • Senior Management experience running diverse healthcare businesses 30 million + Patients treated by AbbVie’s • Strong track record of commercial execution medicines every year • Commercial experience building and maintaining industry-leading franchises • Exceptional su

  20. Slide 20: Attractive Pipeline Opportunities

    Attractive Pipeline Opportunities

  21. Slide 21: Transaction Allows for Continued Strong Investment in Promising, Innovative Science

    Transaction Allows for Continued Strong Investment in Promising, Innovative Science Annual R&D Investment* Designations Granted 14 Breakthrough Designations 10 Fast Track Designations 4 Accelerated Approvals 19 Priority Reviews Major AbbVie Product and Indication Approvals Since 2013 Immunology 3 Ap

  22. Slide 22: AbbVie's Strong Pipeline Augmented with Numerous Attractive Opportunities

    AbbVie’s Strong Pipeline Augmented with Numerous Attractive Opportunities Phase 1 Phase 2 Registrational/Phase 3 Recent Approvals ABBV-011: SCLC Venclexta: MDS Venclexta: MM, MCL Venclexta: 1L CLL, R/R CLL, AML (1L) Mivebresib: Solid Tumors Navitoclax: Myelofibrosis Imbruvica: FL (1L), FL/MZL (R/R),

  23. Slide 23: Shareholder Value Creation

    (e\e)@)v/(— Shareholder Value Creation

  24. Slide 24: Synergies Generate Significant Value

    Synergies Generate Significant Value Percent of Total Synergies and Areas of Opportunity Cost Reductions SG&A SG&A • Sales and marketing efficiencies ~40% • Reduce duplicate costs across central support functions & IT systems R&D Manufacturing & Supply Chain ~10% >$2BN • Optimize research & early-st

  25. Slide 25: Balance Sheet Strength Will Be Preserved With Robust Cash Flows

    Balance Sheet Strength Will Be Preserved With Robust Cash Flows Transaction Financing Robust Cash Flow to Reduce Debt  Transaction supported with a $38BN fully  AbbVie affirms its commitment to Baa2/BBB underwritten bridge facility obtained from grade credit rating or better Morgan Stanley and MUF

  26. Slide 26: AbbVie Has a Track Record of Strong Execution

    AbbVie Has a Track Record of Strong Execution, Consistently Meeting or Exceeding Financial Commitments • Ranked 1st or 2nd in our peer group for both revenue and adjusted EPS growth in every year since becoming an independent company* Consistently delivered • Met or exceeded both revenue and adjuste

  27. Slide 27: Combination Creates Diversified Biopharmaceutical Company, Well-Positioned for Sustainable Growth

    Combination Creates Diversified Biopharmaceutical Company, Well-Positioned for Sustainable Growth Unique opportunity to Provides acquire highly Potential for immediate scale Deal significantly attractive and substantial and profitability to mitigates 2023 durable growth shareholder value AbbVie’s Gr

  28. Slide 28: Qobvie

    Qobvie

AbbVie — Merger or Acquisition (June 2019) on 6ix